Diabetes
Do new diabetes drugs show pancreatitis signals in FAERS?
Open access · cc by · source: Europe PMC
FAERS 2019–2021 reports link pancreatitis strongly to DPP-4 inhibitors and GLP-1 RAs, with liraglutide leading within GLP-1s.
How this study connects
Role on claims
Each row is a claim on a concept or method page where this paper supports, challenges, or qualifies the statement. Roles are hand-checked — not a model guess.
Not yet placed on a claim. This paper has study layers, but no concept page yet cites it as support, challenge, or qualifier.
Study at a glance
- Design
- Qualitative / archival — FAERS spontaneous adverse-event disproportionality analysis (ROR, PRR, EBGM, IC) for pancreatitis with GLP-1 RA, DPP-4, and SGLT2 drugs, 2019–2021
- N
- N=2313 · 2,313 pancreatitis reports linked to hypoglycemic agents in FAERS
- Population
- Spontaneous FAERS pancreatitis reports involving GLP-1 RAs, DPP-4 inhibitors, or SGLT2 inhibitors
- Outcome
- Disproportionality signals (ROR/PRR/EBGM/IC) for pancreatitis by drug class and agent
Structured fields used in claim comparison tables when every cited study has a complete layer.
Inspect source passages
Do new diabetes drugs show pancreatitis signals in FAERS?
These passages occur verbatim in the stored paper text. They support the points listed below; they do not verify every statement in the explanation.
What data source and years did this pharmacovigilance study use?
FDA Adverse Event Reporting System (FAERS) database from 2019 to 2021
Which drug classes were compared for pancreatitis reporting?
compare the risk of developing pancreatitis between those using GLP-1 RAs and those using sodium-glucose transport protein 2 (SGLT2) inhibitors and dipeptidyl peptidase 4 (DPP-4) inhibitors
Key findings
Of 2,313 reports, 70.2% involved GLP-1 RAs; DPP-4 ROR 13.2 and GLP-1 ROR 9.65 were elevated; liraglutide had the highest GLP-1 association (ROR 6.83); ~17.7% of reports were serious.
Methodology
Researchers mined FAERS (2019–2021) for pancreatitis with GLP-1 RAs, DPP-4 inhibitors, and SGLT2 inhibitors, requiring concurrence of ROR, PRR, EBGM, and IC for a signal.
Limitations
Not incidence rates or proven causation—spontaneous reporting cannot adjust fully for indication, comorbidity, or reporting bias.
Related papers in this topic
Same topic cluster — not a recommendation engine.